Joyeeta Tahseen Khan, BPharm

Affiliate Member

Research Program:

Cancer Therapeutics

Faculty Rank:

Graduate Assistant

Campus:

University of Arkansas for Medical Sciences

College:

College of Pharmacy

Department:

Pharmaceutical Sciences

Cancer Research Interest

Disease Site Focus: Brain
Research Focus Area: Treatment
Type of Research: Translational
Research Keywords: Glioblastoma
Research Interest Statement: My research focuses on understanding and overcoming therapeutic resistance in aggressive cancers, with a particular emphasis on glioblastoma. I investigate how endosomal lysosomal trafficking and autophagic stress-response pathways enable tumor cell survival following ionizing radiation. My current work examines pharmacologic inhibition of PIKfyve as a strategy to disrupt autophagic flux, impair DNA damage repair, and enhance radiosensitivity in glioblastoma models. Using integrated approaches including clonogenic survival assays, DNA damage analyses, cell-cycle profiling, and live-cell imaging, I aim to identify targetable vulnerabilities that limit tumor regrowth after radiotherapy. Broadly, my research interests lie at the intersection of cancer cell stress adaptation, drug resistance, and translational strategies to improve the efficacy of cancer treatments.

Neupane R, Karthikeyan C, Malla S, [et al., including Khan JT]. Identification and Mechanistic Profiling of Indolin-2-One Derivatives That Induce ROS-Driven Intrinsic Apoptosis in Prostate and Colorectal Cancer Cells. Journal of biochemical and molecular toxicology. 2025 39(11):e70545. PMID: 41121926.
Amawi H, Makhlouf T, Hammad AM, [et al., including Khan JT]. Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorder. Brain research bulletin. 2025 228:111414. PMID: 40460941.